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Abstract
Themolecular mechanisms of vulvar squamous cell carcinoma (VSCC) remain obscure. To this end, we investigated
systematically for the first time the expression profile of VSCC using themicroarray technology, in a total of 11 snap-
frozen samples, from five VSCC patients covering early and advanced stages of VSCC undergoing radical surgery
and from six matched healthy controls. All experiments were performed using Affymetrix Human Genome U133A
2.0 oligonucleotide arrays, covering 22,277 probe sets. Genes were filtered and analyzed using analysis of variance,
t test, fold-change calculations, and unsupervised hierarchical cluster analysis. Further processing included func-
tional analysis and overrepresentation calculations based on Gene Ontology, Database for Annotation, Visualization,
and Integrated Discovery, and Ingenuity Pathway Analysis. The molecular phenotypes of VSCC patients exhibited
significant and discrete transcriptional differences from the healthy controls, whereas principal component analysis
documented that this separation is mediated by a consistent set of gene expression differences. We detected 1077
genes (306 upregulated and 771 downregulated) that were differentially expressed between VSCC patients and
healthy controls by at least twofold (P < .01), whereas a novel subset of patients was revealed displaying a distinct
pattern of 125 upregulated genes involved in multiple cellular processes. Functional analysis of the 1077 genes
documented their involvement in more than 50 signaling pathways, such as PTEN, oncostatin M, and extracellular
signal–regulated kinase signaling, affecting extracellular matrix remodeling and invasion. Comparison of our data
set with those of the single VIN study revealed that the two entities share a limited number of genes and display
unique features.
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Introduction
Vulvar carcinoma, although a rare form of all female genital malig-
nancies, represents the fourth most common gynecologic cancer,
exhibiting an overall incidence of approximately 1.5 per 100,000
women-years. However, this low rate increases significantly with
age, reaching up to 20 per 100,000 women-years after the age of
75 [1]; histologically, the most common type is manifested as vulvar
squamous cell carcinoma (VSCC), accounting for 80% to 90% of
the cases [2]. In contrast to the increasing frequency of its precursor
premalignant lesion, that is, vulvar intraepithelial neoplasia (VIN)
[3], which is prevalent in women of relatively younger age and usu-
ally associated with human papillomavirus (HPV) infection, vulvar
carcinoma remained stable during the last 40 years [1], exhibiting
a rather lower overall frequency of HPV infection [4] as reflected
by the individual frequencies of its four histologic subtypes [4–7].
The unique features of these two disorders have made them very infor-
mative models to investigate the actual molecular pathways resulting in
the sequential transformation of the vulvar epithelium and its evolution
to squamous cell carcinoma. These discrete differences also imply that,
besides the HPV component required for the initial generation of VIN,
additional risk factors are needed for the evolution to VSCC, including
chronic vulvar inflammation, smoking, immunodeficiency status, and
increasing age [8].
The recent reclassification of VIN terminology by the International
Society for the Study of Vulvovaginal Diseases [9] replaced the previ-
ous three subclassifications of VIN 1 to 3 and introduced the sub-
division of VIN into the (a) usual type, comprising the high-grade
lesions 2 and 3 occurring mainly in younger women, and the (b) dif-
ferentiated type, encompassing the previous type of differentiated
VIN 3. It is of interest that this reclassification has greatly facilitated
the matching of the two putative discrete pathogenetic pathways lead-
ing to the development of VSCC; the usual type requiring the pres-
ence of HPV infection, mediated by oncogenic subtypes such as 16,
18, 31, and 33, whereas the differentiated type, mostly developing in
older women on a background of lichen sclerosis or squamous cell
hyperplasia, does not [10]. Thus, the two resulting pathogenetic types
of VSCC, which can be considered to arise from the two corresponding
pathways, are the basaloid or warty type, derived from the usual VIN
pathway through a long transition period, occurring in younger women
and associated with HPV [11], and the keratinizing type, originating
through the differentiated VIN pathway [6] through a rapid progres-
sion, occurring in older women not linked with HPV infection [3].
To clarify the precise molecular events leading to the two types of
VSCC, recent studies have attempted to correlate several cell cycle–
related parameters with the two pathways leading to VSCC [10,12].
In the classic form, high levels of coexpression of p14ARF and
p16INK4A were found in most classic VIN lesions and were correlated
with the degree of dysplasia and the presence of HPV [10], whereas
most of the cases of either differentiated VIN or keratinizing VSCC
were found to be negative for HPV, exhibited very low frequency of
combined expression of p14ARF and p16INK4A, and occurred in older
women [10]. A further study by the same group [12] confirmed the
previous findings and extended the capacity of accurately distin-
guishing the two pathways by the implementation of a robust
immunohistochemical panel involving p16INK4A, p53, and MIB1, a
monoclonal antibody for the proliferation marker Ki-67. Other studies
documented the role of the endothelin axis in tissue microarrays with
VSCC; particularly, receptor ETBR was found to be a prognostic factor,
whereas its expression correlated with disease progression [13]. Ex-
pression of the 14-3-3-σ protein, also named stratiffin, which promotes
G2/M cell cycle arrest, was found immunohistochemically to be down-
regulated in a subset of VSCC, suggesting a putative role in its devel-
opment [14]. Furthermore, a series of additional individual molecular
markers have been investigated in VSCC, and their roles in the path-
ogenesis, progression, or prognosis have been extensively reviewed re-
cently [15]. However, owing to the single-parameter approach by these
limited studies, no concrete conclusions can be generated regarding the
role of these markers in the pathogenesis of VSCC. Recently, a multi-
parameter approach using the microarray technology was used for the
analysis of HPV-related VIN and documented that VIN is inherently a
highly proliferative disorder, without displaying, however, dysregula-
tion of apoptosis or angiogenesis [16].
In view of these limited data on the pathogenesis of VSCC, in the
present study, we opted a systematic approach to delineate for the
first time the molecular markers and the cellular pathways involved
in the pathogenesis of VSCC by analyzing the gene expression profile
of VSCC using the microarray technology [17].
Materials and Methods
Patients and Samples
A total of 11 snap-frozen samples were analyzed, derived from five
VSCC patients undergoing radical vulvectomy with lymphadenec-
tomy and from six matched healthy control samples of histologically
normal vulvar tissue obtained by vulvar biopsy from patients under-
going surgery for benign gynecologic diseases, such as uterine pro-
lapse. The tumor samples were classified according to the 2009
vulvar cancer staging system of the International Federation of Gyne-
cology and Obstetrics [18] and the histologic classification system of
the World Health Organization. All tissues were obtained using in-
formed consent after the approval from the institutional ethical com-
mittee of the Alexandra Hospital. None of the patients had received any
preoperative chemotherapy or irradiation treatment.
HPV DNA Genotyping
The linear-array HPV genotyping test (CE-IVD), a strip-based qual-
itative in vitro assay (Hoffmann-La Roche Ltd, Basel, Switzerland),
was used for the detection of the low-risk and high-risk genotypes of
HPV in vulvar cells [19]. The test uses amplification of target DNA
by polymerase chain reaction and nucleic acid hybridization for the
detection of 37 low-risk and high-risk genotypes of HPV. The detec-
tion of amplified DNAwas performed using an array of oligonucleotide
probes that permits independent identification of HPV genotypes. The
method detects with high sensitivity 24 low-risk types (6, 11, 26, 40,
42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84,
IS39, and CP6180) and 13 high-risk types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68). The method uses two internal controls of
β2-microglobulin with low and high concentration. All samples were
tested twice.
RNA Preparation
Total cellular RNA from the 11 snap-frozen samples was prepared
using TRIzol (Invitrogen by Life Technologies, Carlsbad, CA) and
was further purified by using phenol/chloroform/isoamyl alcohol
(25:24:1 vol/vol/vol) extraction [20].
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Experiments were performed using Affymetrix Human Genome
U133A 2.0 oligonucleotide arrays (Affymetrix, Santa Clara, CA) as
described (http://www.affymetrix.com/support/technical/datasheets/
human_datasheet.pdf ). Total RNA from each sample was used to
prepare biotinylated target complementary RNA, with minor modifica-
tions from the manufacturer’s recommendations (expression_manual.
affx). The quality and amount of starting RNA were confirmed using
an agarose gel.
Briefly, 5 μg of messenger RNA was used to generate first-strand
complementary DNA by using a T7-linked oligo(dT) primer. After
second-strand synthesis, in vitro transcription was performed with
biotinylated UTP and CTP (Affymetrix), resulting in an approxi-
mately 300-fold amplification of RNA. The target complementary
DNA generated from each sample was processed as per the manufac-
turer’s recommendation using an Affymetrix GeneChip Instrument
System (expression_manual.affx). Briefly, spike controls were added
to 15 μg of fragmented complementary RNA before overnight hy-
bridization. Arrays were then washed and stained with streptavidin-
phycoerythrin before being scanned on an Affymetrix GeneChip
scanner. After scanning, array images were assessed by eye to confirm
scanner alignment and the absence of significant bubbles or scratches
on the chip surface. A complete description of these technical proce-
dures is available at the following Web site: https://www.affymetrix.
com/support/technical/manuals.affx.
The individual 3′/5′ ratios for glyceraldehyde-3-phosphate dehydro-
genase and β-actin were confirmed to be within acceptable limits (1.2-
3.03 and 0.8-1.5, respectively), whereas BioB spike controls were found
to be present on all chips, with BioC, BioD, and CreX also present in
increasing intensity. When scaled to a target intensity of 150 (using
Affymetrix MAS 5.0 array analysis software), scaling factors for all
arrays were within acceptable limits (0.59-1.45), as were background,
Q values, and mean intensities. Details of quality control measures
can be found at http://www.ncbi.nlm.nih.gov/geo/.
Data Analysis
Gene-level RMA sketch algorithm (Partek Genomics Suite 6.5;
6.10.0810; St Louis, MO) was used for normalizing and calculating
the summarized probe set values. Genes were filtered and analyzed
using analysis of variance, t test, fold-change calculations, and unsu-
pervised hierarchical cluster analysis (Partek Genomics Suite 6.5;
6.10.0810; and TIBCO Spotfire DecisionSite for Functional Geno-
mics, Somerville, MA). Further processing included functional anal-
ysis and overrepresentation calculations based on Gene Ontology (GO)
Annotation Tool and publication data of Database for Annotation,
Visualization, and Integrated Discovery (http://david.abcc.ncifcrf.gov/)
[21,22] and Ingenuity Pathway Systems. Overrepresentation calcula-
tions were performed using Ease (http://david.abcc.ncifcrf.gov/). Data
results are deposited in http://www.ncbi.nlm.nih.gov/geo/. Principal
component analysis (PCA) of microarray results was performed with
S-plus (version 6.1; Insightful Corp, Seattle, WA; www.insightful.
com/support/splus61win).
Results
Clinicopathologic Data
The clinical parameters and the histopathologic features of the
patients with VSCC and of the healthy controls are summarized in
Table 1. The patients covered both early and advanced stages of
VSCC and displayed no tumor progression after radical vulvectomy
and lymphadenectomy.
Global Expression Profile Analysis of VSCC
The global gene expression profile analysis between the samples
from patients with VSCC and those from the healthy controls was
performed by using the Affymetrix Human Genome U133A 2.0
microarray platform, covering 22,277 probe sets and 500,000 distinct
oligonucleotide features, representing 14,500 well-characterized human
genes. Initially, data were subjected to unsupervised hierarchical clus-
tering analysis to identify subgroups of samples that may exhibit dis-
crete molecular phenotypes. The analysis included five VSCC and six
healthy control samples, each sample treated as a 22,277-dimension
vector (based on the total probe sets in the array), and the Euclidean
distance between samples was established and used as the metric dis-
tance. As shown in Figure 1, a clear distinction between vulvar cancer
patients and healthy control individuals was documented. These data
are consistent with the fact that the molecular phenotypes in vulvar
cancer exhibit significant and discrete transcriptional differences from
the normal.
We next investigated the presence of underlying patterns in gene
expression data from the microarray experiment by performing un-
supervised PCA. This linear projection method reduces the dimen-
sionality of microarray data and permits the visualization of the
relatedness between genes and/or samples that it clusters. When
PCA was performed using data from 1077 differentially expressed
genes, it demonstrated a dramatic separation between controls and
VSCC samples as shown in Figure W1. This finding actually indi-
cates that this separation is mediated by a consistent set of gene ex-
pression differences.
Differential Expression of VSCC-Specific Genes and a
Novel Subset of VSCC Patients
On the basis of these findings, we next searched for the identifi-
cation of the genes responsible for the establishment of the aberrant
expression profile in VSCC, leading to a distinctive phenotype from
the normal state. Using the t test method, we detected 1077 genes
that were differentially expressed between the tumor and the normal
samples by at least twofold with statistical significance (P < .01), as
shown in Table W1, which contains a complete listing of all the dif-
ferentially expressed genes. A heat map displaying the differential ex-
pression of these genes is shown in Figure 2. It is noteworthy that the
downregulated genes were found to be common to all five tumor
samples. However, samples 1 and 2 displayed a quite distinct pattern
of upregulated genes, suggesting the presence of a putative subset
operating in VSCC and exhibiting significant differences at the level
of the transcriptome. These differences were further investigated
among the group of the 306 upregulated genes in the tumor samples
(Figure 2). Their analysis revealed a distinct set of 125 genes, with a
fold change greater than 2.0 (P < .01) as shown in Table W2. GO
analysis of the set of these upregulated 125 genes in the two tumor
samples revealed that most of these genes are involved in the biologic
processes of cell death, cell-to-cell signaling and interaction, cellular
development, cellular growth and proliferation, cellular movement,
and cellular assembly and organization. Their differential expression
among the vulvar cancer samples may thus represent the basis for
explaining these discrete molecular phenotypes.
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Furthermore, of the 1077 differentially expressed genes, 306 were
upregulated and 771 were downregulated compared with healthy
controls, as shown in Table W1. A representative list of these genes
exhibiting the highest and lowest levels of fold expression is shown in
Table 2, A and B, respectively. Among these genes exhibiting marked
up-regulation, there are many critical genes, such as the matrix metallo-
proteinases 1 and 12 (MMP1 and MMP12), the interleukin 1 family
member 9 (IL1F9), the periostin or osteoblast-specific factor (POSTN ),
the interleukin 1 alpha (IL1A), and interleukin 24 (IL24 ), which are
well characterized as cancer markers and are involved in the process of
tumorigenicity. In addition, several regulatory genes relevant to carci-
nogenesis displayed excessive down-regulation, such as endothelin 3
(END3), complement factorD (adipsin), the two detoxification proteins
cytochrome P450, family 4, subfamily B, polypeptide 1 (CYP4B1) and
glutathione peroxidase 3 (GPX3), and chemokine (C-X-Cmotif ) ligand
12 or stromal cell–derived factor (CXCL12), implicated in metastasis of
some cancers, and the pleiomorphic adenoma gene-like 1 (PLAGL1)
tumor suppressor gene.
Functional Characterization of the Differentially Regulated
Genes in VSCC
To functionally characterize the differentially regulated 1077
genes, we performed GO analysis using the Ingenuity Pathway Anal-
ysis software. The genes were found to be distributed among several
functional classes; of the 20 identified classes, the most significant
ones were cellular growth and proliferation, cell death, cellular devel-
opment, cellular movement, cell cycle, and others as depicted in Ta-
ble 3. A more detailed analysis of the individual number of genes
exhibiting either up-regulation or down-regulation in each of the
20 functional groups is depicted in Figure 3. The most abundant
upregulated genes belonged to the biologic process of cellular growth
and proliferation, whereas the most downregulated genes involved
the categories of cellular growth and proliferation, cell death, and cel-
lular development.
Figure 2. Hierarchical clustering of the tumor (lanes T1-T5) and nor-
mal samples (lanes N1-N5). A set of 1077 filtered genes was used to
differentiate between the two groups with a threshold of at least
twofold (P < .01). The individual lane numbers (T1-5 and N1-5) cor-
respond to the numbers of the patients (1-5) and controls (1-5) of
Table 1, respectively. There is a clear distinction between the tumor
and normal samples. The downregulated probe sets are common
to all tumor samples; however, tumor samples in lanes T1 and T2
display a small cluster of 125 genes with a clearly distinct pattern
of up-regulation compared with tumor samples T3, T4, and T5. Un-
supervised hierarchical clustering, average linkage, and Spearman
rank correlation method were used for distance metric selection.
Gene expression values are color coded from bright red (most up-
regulated) to bright green (most downregulated).
Figure 1. Agglomerative unsupervised hierarchical clustering of the
microarray data from tumor and normal samples groups. Although a
high diversity is seen within each group, there is a clear division be-
tween the two groups as represented by the different clusters. A dis-
tance matrix was computed using the Euclidean distance method.
N indicates normal samples; T, tumor samples (VSCC).
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Analysis of Pathways Aberrantly Operating in VSCC
To further characterize the functional significance of the 1077
genes with the altered expression patterns, we performed a systematic
analysis of the set of genes included in the list in Table W1, exhibit-
ing a differential expression level between the two groups by at least
twofold (P < .01), and searched for gene classifiers and pathways that
are significantly enriched between the two groups by using the Inge-
nuity Pathway Analysis software. More than 50 signaling pathways,
each involving more than five genes, were detected and considered
significant (P < .05), documenting that VSCC affects many cyto-
kines and signaling molecules involved in numerous signaling proce-
dures or pathways. In the top 20 affected signaling pathways, we
Table 2. Top 30 Significantly Upregulated (A) and Bottom 30 Significantly Downregulated (B) Genes in VSCC.
Affymetrix ID Gene Symbol Description Type(s) Fold Change
(A) Fold change > 2, P < .01
204475_at MMP1 Matrix metallopeptidase 1 Peptidase 33.29
220322_at IL1F9 Interleukin 1 family, member 9 Cytokine 12.13
204580_at MMP12 Matrix metallopeptidase 12 (macrophage elastase) Peptidase 11.04
210809_s_at POSTN Periostin, osteoblast specific factor Other 10.76
210118_s_at IL1A Interleukin 1, α Cytokine 8.69
203915_at CXCL9 Chemokine (C-X-C motif) ligand 9 Cytokine 8.56
209800_at KRT16 Keratin 16 Other 6.69
206569_at IL24 Interleukin 24 Cytokine 6.25
202236_s_at SLC16A1 Solute carrier family 16, member 1 Transporter 6.07
205943_at TDO2 Tryptophan 2,3-dioxygenase Enzyme 5.73
212365_at MYO1B Myosin IB Other 5.05
215177_s_at ITGA6 Integrin, α6 Other 4.92
214446_at ELL2 Elongation factor, RNA polymerase II, 2 Transcription regulator 4.70
201490_s_at PPIF Peptidylprolyl isomerase F Enzyme 4.55
203234_at UPP1 Uridine phosphorylase 1 Enzyme 4.41
205067_at IL1B Interleukin 1, β Cytokine 4.40
203921_at CHST2 Carbohydrate sulfotransferase 2 Enzyme 4.36
202693_s_at STK17A Serine/threonine kinase 17a Kinase 4.34
203936_s_at MMP9 Matrix metallopeptidase 9 Peptidase 4.16
216918_s_at DST Dystonin Other 4.15
211981_at COL4A1 Collagen, type IV, α1 Other 4.00
211643_x_at IGKC Immunoglobulin κ constant Other 3.91
209398_at HIST1H1C Histone cluster 1, H1c Other 3.91
204420_at FOSL1 FOS-like antigen 1 Transcription regulator 3.87
204858_s_at TYMP Thymidine phosphorylase Growth factor 3.81
210904_s_at IL13RA1 Interleukin 13 receptor, α1 Transmembrane receptor 3.68
214074_s_at CTTN Cortactin Other 3.68
202267_at LAMC2 Laminin, γ2 Other 3.64
203256_at CDH3 Cadherin 3, type 1, P-cadherin (placental) Other 3.63
206513_at AIM2 Absent in melanoma 2 Other 3.62
(B) Fold change < −2, P < .01
205694_at TYRP1 Tyrosinase-related protein 1 Enzyme −22.84
205382_s_at CFD Complement factor D (adipsin) Peptidase −15.61
208399_s_at EDN3 Endothelin 3 Other −15.58
210096_at CYP4B1 Cytochrome P450, family 4, subfamily B, polypeptide 1 Enzyme −15.22
204719_at ABCA8 ATP-binding cassette, subfamily A (ABC1), member 8 Transporter −13.79
209613_s_at ADH1B Alcohol dehydrogenase 1B (class I), β polypeptide Enzyme −10.84
219295_s_at PCOLCE2 Procollagen C-endopeptidase enhancer 2 Other −10.54
209318_x_at PLAGL1 Pleiomorphic adenoma gene-like 1 Transcription regulator −9.88
209687_at CXCL12 Chemokine (C-X-C motif) ligand 12 Cytokine −9.45
201348_at GPX3 Glutathione peroxidase 3 (plasma) Enzyme −9.33
206104_at ISL1 ISL LIM homeobox 1 Transcription regulator −8.86
204731_at TGFBR3 Transforming growth factor, β receptor III Kinase −8.56
204235_s_at GULP1 GULP, engulfment adaptor PTB domain containing 1 Other −8.53
205200_at CLEC3B C-type lectin domain family 3, member B Other −8.36
213397_x_at RNASE4 Ribonuclease, RNase A family, 4 Enzyme −8.30
201540_at FHL1 Four-and-a-half LIM domains 1 Other −8.25
216333_x_at TNXB Tenascin XB Other −8.07
207206_s_at ALOX12 Arachidonate 12-lipoxygenase Enzyme −7.70
209894_at LEPR Leptin receptor Transmembrane receptor −7.69
216733_s_at GATM Glycine amidinotransferase Enzyme −7.68
207761_s_at METTL7A Methyltransferase like 7A Other −7.64
220013_at EPHX3 Epoxide hydrolase 3 Enzyme −7.64
221748_s_at TNS1 Tensin 1 Other −7.27
208335_s_at DARC Duffy blood group, chemokine receptor G protein–coupled receptor −7.22
201525_at APOD Apolipoprotein D Transporter −7.19
203706_s_at FZD7 Frizzled homolog 7 (Drosophila) G protein–coupled receptor −7.18
202995_s_at FBLN1 Fibulin 1 Other −7.10
212865_s_at COL14A1 Collagen, type XIV, α1 Other −6.97
205392_s_at CCL14 Chemokine (C-C motif) ligand 14 Cytokine −6.74
209604_s_at GATA3 GATA binding protein 3 Transcription regulator −6.69
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located PTEN signaling (20 genes), oncostatin M signaling (10 genes),
extracellular signal–regulated kinase (ERK) signaling (14 genes), and
other significant pathways related to cancer as shown in Figure W2.
Specifically, the pathway analysis tool revealed that the most significantly
upregulated pathway in VSCCwas the one related to interleukin 6 (IL-6)
signaling and oncostatin M signaling, with the involvement of key reg-
ulatory genes, such asMMP1 andMMP12, andNRAS, affecting major
cellular processes, such as cell adhesion, extracellular matrix (ECM) re-
modeling, and invasion, as shown in Figure 4.
In addition, significant differences were found also among genes
playing a key role in the regulation of cell division. Both cell division
cycle 25 homologs C and B (CDC25C and CDC25B) were found to
be markedly upregulated by 1.64- and 2.01-fold, respectively, among
the VSCC samples compared with healthy controls (P < .05), as
shown in Figure 5. These two genes have been recently documented
to play a crucial role in the pathogenesis and progression of VSCC
[23]. The network generated by the key upregulated and down-
regulated genes affected by CDC25C and CDC25B is depicted in
Figure 6. One of the major interactors of CDC25, the androgen recep-
tor (AR), was found to be significantly downregulated in the VSCC
samples by 3.59-fold. This finding, combined with the most excessive
down-regulation of an important member of a cell proliferation axis
Table 3. Distribution into 20 Functional Classes of the 1077 Genes Differentially Expressed
between the Tumor and the Normal Samples by Twofold.
Molecular Function (GO) No. Genes P
Cellular growth and proliferation 330 7.89e − 07
Cell death 302 6.95e − 05
Cellular development 279 4.80e − 10
Cellular movement 225 1.07e − 10
Cellular assembly and organization 154 1.87e − 05
Cell morphology 149 3.56e − 07
Cell cycle 147 1.01e − 06
Gene expression 132 5.62e − 05
Small-molecule biochemistry 77 8.81e − 05
Posttranslational modification 66 1.18e − 03
Cell-to-cell signaling and interaction 57 1.18e − 03
Amino acid metabolism 52 6.86e − 04
Cellular function and maintenance 34 2.33e − 03
Cell signaling 29 1.93e − 03
Carbohydrate metabolism 28 8.81e − 05
Protein synthesis 28 4.69e − 03
Molecular transport 24 8.81e − 05
Lipid metabolism 7 7.83e − 04
Cellular compromise 7 4.76e − 03
Drug metabolism 3 2.56e − 03
Figure 3. Functional grouping of the 1077 filtered genes differentiating between the two groups. The filtered genes exhibited either up-
regulation (blue bars) or down-regulation (red bars) with a threshold of at least twofold (P < .01). The numbers on the y axis denote the
total number of genes in each functional class that are either upregulated (blue) or downregulated (red).
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such as endothelin 3 (EDN3) by 15.58-fold and its receptor type B
(EDNRB) by 4.34-fold, as shown in Tables 2B and W1, is consistent
with an aberrant reduction of paracrine and endocrine functions of the
tumor cells (Figure 6). A more systematic analysis to this direction,
using the pathway analysis tool, revealed another important network
generated by genes exhibiting significant down-regulation in the VSCC
samples and involving the AR gene (Figure 7). Interestingly, the genes
affected and interacting with the AR gene are related to (a) cancer, such
as the ZMIZ1 gene regulating the activity of various transcription fac-
tors, including Smad3/4 and p53 and associated with acute lympho-
blastic leukemia, and the ARMCX2 gene, a member of the ALEX
family of proteins playing a role in tumor suppression; and (b) signal
transduction such as the IL6ST, a signal transducer shared by many
cytokines, including IL-6, ciliary neurotrophic factor, leukemia inhib-
itory factor, and oncostatin M.
Comparative Analysis of the Data Set to Proposed Markers
for VSCC
On the basis of the limited available data of molecular markers for
vulvar carcinoma found to be important either in the pathogenesis
Figure 4. Oncostatin M signaling pathway. Within this pathway, the network of cell adhesion and extracellular remodeling is the most
significantly upregulated network in VSCC. The latter was generated from critical genes most upregulated in the tumor samples, depict-
ing the major nodes of MMPs 1, 2, and 13 and their interactors. Red depicts the genes that are upregulated in tumor samples. The
intensity of the colors indicates the magnitude of regulation.
Figure 5. Up-regulation at the transcriptional level of CDC25C and
CDC25B genes in the samples of VSCC compared with healthy
controls. The corresponding probe sets of the Affymetrix Human
Genome U133A 2.0 oligonucleotide arrays were used for this com-
parison. The numbers at the y axis indicate arbitrary units.
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and/or in the progression or in the clinical outcome of vulvar carcinoma
[15], we have analyzed our data for the aberrant expression of such pro-
posed markers. Our search actually documented a limited list of such
proposed genes, exhibiting significant changes in their expression pro-
file, as shown in Table W3. Of these genes, the VEGFA gene, inducing
angiogenesis and promoting cell migration, and the antiapoptotic
BCL2 gene displayed the most upregulated and downregulated expres-
sion, respectively.
Figure 6. Network of cycle control highlighting the up-regulation of the key homologs CDC25C and CDC25B and their interacting com-
ponents involved in cell cycle control, proliferation, and nuclear signaling. Note the significant down-regulation of AR directly affected
by CDC25B. Solid lines indicate direct interactions; dashed lines, indirect interactions.
Figure 7. Network generated from the genes downregulated in the tumor samples. The genes present in the network include AR and its
direct interactors. The network also contains genes related to cancer, inflammatory disease, and connective tissue disorders.
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Comparative Analysis of the VSCC versus the VIN Data Set
Because our study is the first one to systematically analyze the
transcriptional profile of vulvar carcinoma, and in view of the fact
that there is only one study in the literature on the precursor of vul-
var carcinoma, that is, VIN [16], using the same approach, we per-
formed a direct comparison between the two data sets. From the
1497 genes significantly changed in the VIN data set, there are
158 common genes present within the gene list generated from
our samples. Of these, 21 genes were upregulated in both VIN
and VSCC (Table W4 and Figure 8), whereas 121 genes were sig-
nificantly downregulated in both clinical entities (Table W5 and Fig-
ure 9). Only 18 genes showed a different expression profile in the
two data sets. Using the Wilcoxon signed rank test, the gene expres-
sion levels of the upregulated genes between the VIN and VSCC data
sets did not differ between the two entities (P > .10). Most of the
common upregulated genes are involved in functions related with cell
cycle, DNA replication, recombination and repair, and cell death. In
the 121 common downregulated genes, using the Wilcoxon signed
rank test, the decrease in the level of expression was higher in VSCC
(P < .001). Most of those genes were found to be related with cellular
development (PLAG1), cellular movement (FHL1), and cellular
growth and proliferation (TGFBR3).
Furthermore, it is noteworthy that several key gene regulators of
cell proliferation, such as the glutathione peroxidase 3 (GPX3), which
functions in the detoxification of hydrogen peroxide, the tumor sup-
pressor PLAG1 and the RNASE4 gene playing an important role in
messenger RNA cleavage, displayed a pattern of gradual but pro-
nounced quantitative down-regulation from VIN to VSCC
(Tables W4 and W5), implying that this evolving differential expres-
sion reflects the operating aberrant specific molecular events and
mechanisms, leading eventually to the vulvar carcinoma status.
Discussion
In the present study, we performed a comprehensive analysis of the
VSCC transcriptome and compared it to that of a matched normal
vulvar epithelium. To our knowledge, this is the first study to de-
scribe the expression profile of this important form of cancer in a
cohort of well-characterized VSCC patients of different clinical stages
and histopathologic types. In view of the limited data on the patho-
genesis of VSCC, our primary goal was to delineate the molecular
parameters and reveal the cellular pathways involved in the pathogen-
esis of VSCC by using the microarray technology [17]. Our second-
ary aim was to compare the expression profile of the established stage
of VSCC to that of its well-studied precursor, namely, the VIN,
thanks to the available data of the single molecular study performed
up-to-date [16], to gain insights into the evolutionary pathways of vul-
var carcinogenesis. We have documented a high number of upregulated
Figure 8. Venn diagram showing the identification of the 21 common genes upregulated both in the VIN [16] and in the present study of
VSCC patients. The identified 21 genes are mostly involved in the biologic processes of cell cycle, DNA replication, recombination and
repair, and cell death. Results were obtained by applying the Student’s t test. A cutoff of .01 for the adjusted P value was applied. Circle
radii (light blue for VIN; light orange for VSCC) are proportional to the number of transcripts differentially expressed in each condition.
Figure 9. Venn diagram showing the identification of the 121 com-
mon genes downregulated both in the VIN [16] and in the present
study of VSCC patients. The identified 121 genes are involved in the
Wnt/β-catenin signaling (TCF4 transcription factor), in human embry-
onic stem cell pluripotency signaling pathway, like the FGFR1 gene,
and in acutemyeloid leukemia signaling, like the KIT gene. A cutoff of
.01 for the adjusted P value was applied. Circle radii (light blue for
VIN; light orange for VSCC) are proportional to the number of tran-
scripts differentially expressed in each condition.
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and downregulated genes in VSCC affecting primarily the biologic pro-
cesses of cellular growth and proliferation and specifically those of ECM
remodeling and invasion and cell cycle proliferation pathways. These
data are in contrast to those of the VIN expression profile [16], which
are mainly characterized by increased proliferation and decreased cell
communication processes.
The VSCC status induced a coordinated and aberrant expression
of multiple genes involved primarily in cell growth and proliferation
and in cell death, affecting more than 50 signaling pathways. The
most important characteristic feature of the aberrant expression pro-
file of the 1077 studied genes in our series of VSCC, reflecting an
extensive ECM remodeling, was the pronounced up-regulation of
two members of the MMP family, namely, MMP1 and MMP12,
and, to a lesser extent, of two additional members, namely, MMP9
and MMP11, composed of more than 28 enzymes and representing
the major proteases with the ability to degrade most of the compo-
nents of the ECM, through a combined cleavage and release of bio-
active molecules, which promote invasion and angiogenesis [24].
This activity leads to extensive ECM remodeling and cell migration.
The latter function is an essential step for tumor invasion and me-
tastasis [24], and thus, their role in the later stages of tumor devel-
opment is consistent with the clinical stages of our patients (Table 1).
It is noteworthy that besides these unique properties of MMPs ex-
erted at the late stages of tumorigenesis, MMPs have been shown
recently to affect also cellular signaling pathways activated at the early
stages of tumor formation, by stimulating epithelial-mesenchymal
transition during tumorigenesis, although the identification of the
cell surface targets of MMPs in inducing epithelial-mesenchymal
transition has not yet been accomplished [25]. It is important to
note that there is no consistent pattern of MMP expression in the
various types of cancers studied, suggesting an intrinsic tissue het-
erogeneity of the various parameters of ECM components [25]. In
our study, within the context of the oncostatin M signaling pathway,
MMP1 andMMP12 exhibited primarily a significant up-regulation,
along with a moderate up-regulation of MMP9 and MMP11
(Table 2A and Figure 4). Particularly, MMP1 or interstitial collage-
nase gene encodes a secreted enzyme cleaving interstitial collagens,
types I, II and III, whereas MMP12 or macrophage elastase encodes
for an enzyme that degrades soluble and insoluble elastin and par-
ticipates with other MMPs in the ECM remodeling. MMP9 or
gelatinase B, conversely, may play an essential role in local prote-
olysis of the ECM and in leukocyte migration and degrades fibro-
nectin, whereas MMP11 or stromelysin 3, codes for an enzyme,
which is activated intracellularly by furin within the constitutive se-
cretory pathway. Also, in contrast to other MMPs, this enzyme
cleaves α1-proteinase inhibitor but weakly degrades structural pro-
teins of the ECM.
The high expression of these four MMPs in VSCC represents a
genuine feature of advanced cancer status; however, this extensive re-
modeling seems to be mediated also by the reduced expression of the
natural tissue inhibitors of metallopeptidases (TIMPs), which nor-
mally reduce excessive proteolytic ECM degradation by MMPs, thus
controlling the extent of remodeling. Actually, this is corroborated in
our studies by the significant down-regulation of the TIMP3 gene by
more than fivefold (Table W1 and Figure 4). Although the aberrant
expression of MMPs has been associated with poor prognosis [25], in
our series, all five patients have accomplished a more than 5-year sur-
vival period and had no local recurrence or distant metastases. Appar-
ently, this can be partly attributed to the rather early clinical stages
and the prompt radical treatment they all received, involving bilateral
inguinal and femoral node dissection (Table 1).
Another key gene that has exhibited a significant up-regulation in
VSCC, a feature compatible with the concept of invasive phenotype,
was periostin or osteoblast specific factor (POSTN), a mesenchyme-
specific gene inducing cell attachment and playing an important role
in cell adhesion. The inducible overexpression of POSTN in tumor
cell lines can lead to significant tumor progression and angiogenesis
in immunocompromised animals. The latter effect seems to be me-
diated through an integrin αvβ3–focal adhesion kinase signaling
pathway [26]. This interesting mechanism of acquired angiogenesis
by POSTN leading to tumor promotion may thus represent a crucial
role in the advanced stages of VSCC. However, it should be noted
that other studies in bladder cancer have shown that POSTN is
significantly downregulated and suppresses cell invasiveness and
metastasis of cancer cells through the TAB1/TAK1 signaling path-
way [27]. Thus, it is conceivable that these differences might re-
flect the operation of additional tissue-specific factors of the
individual tumor types, interacting with the two discrete signal-
ing pathways.
Within the context of the major pathways affected in VSCC, such
as the cellular growth and proliferation and cell cycle (Figure 3), the
two major homologs of cell division cycle 25, namely, CDC25C
and CDC25B, were found to display moderate but significant up-
regulation, affecting the control of cell cycle and other key regulators
in the involved networks (Figure 6). CDC25B is a member of the
CDC25 family of phosphatases and activates the cyclin-dependent
kinase CDC2 by removing two phosphate groups and is required for
entry into mitosis. CDC25B has oncogenic properties, although its
role in tumor formation has not been determined. Multiple transcript
variants for this gene exist. CDC25C, however, plays a much more
important role in cell cycle by directing dephosphorylation of cyclin
B–bound CDC2 and triggering entry into mitosis. It is also thought
to suppress p53-induced growth arrest. These features make CDC25
phosphatases key participants in the process of malignant transfor-
mation after their abnormal expression. Their overexpression in several
types of human cancer has been previously detected but not in vulvar
cancer [28]. Recently, however, CDC25C and phosphorylated
CDC25C (Ser216) were found to play a major role, whereas CDC25B
was found to play a minor role in the pathogenesis and progression of
VSCC. Overexpression of all three forms occurring at a later clin-
ical stage was associated with an aggressive phenotype and poor
prognosis [23]. Interestingly, the three isoforms were not inde-
pendently correlated to prognosis, indicating that they may operate
through independent pathways [28]. Actually, in our series of
VSCC, the up-regulation of CDC25C and CDC25B was moderate
occurring in rather early clinical stages and was associated with a
rather good prognosis and survival, consistent with data of a Nor-
wegian study [23].
The gene coding for the potent vasoactive ligand endothelin 3
(EDN3) has been found to display one of the most pronounced
down-regulation, that is, −15.58-fold among the 1077 differentially
expressed genes in our VSCC series. This was followed also by a
concomitant down-regulation of endothelin 1 (EDN1) and their
receptors EDNRB and EDNRA, by −1.36-, −4.34-, and −1.61-fold,
respectively. Interestingly, a pattern of similar magnitude has been
documented in the VIN study [16], where EDN3, EDNRB, and
EDNRA exhibited a significant down-regulation of their expression
by −12.1-, −2.2-, and −3.1-fold, respectively. Considering the
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precancerous state of VIN, data from the VIN study and from our
study document that the operation of the so-called ET axis is affected
at the earliest steps of vulvar carcinogenesis, within the context of
decreased communication, occurring both in VIN [16] and in cancer
in general [29] and thus do not lend support to recent findings
based on a semiquantitative immunohistochemical analysis on the
relative expression of EDN1 and EDNRB in early stages of vulvar
cancer [13].
Regarding the genomic status of the vulvar neoplasia and the re-
sulting recurrent imbalance in VSCC, of the 10 most upregulated
genes in our study (Table 2A), the expression of IL24 and SLC16A1
combined with their genomic location at 1q32 and 1p12, respectively,
is consistent with the recently observed gain events in the chromosomal
regions 1p and 1q in VSCC using high-resolution genomic profiling
[30]. Similarly, the down-regulation of GPX3, CXCL12, and CLEC3B
located at 5q33.1, 10q11.21, and 3p21-31, respectively, is consistent
with the independently observed rather infrequent (17%-33%) dele-
tions of the corresponding chromosomal regions in a limited number
of VSCC cases [30].
The evolution of VIN to VSCC through two discrete pathways
represents an ideal model to identify the basic molecular mecha-
nisms leading to the established cancerous state. Most of our patients
belonged histologically to the keratinizing type, which results
through a rapid progression from the differentiated VIN pathway.
Both the advanced age of the patients and the lack of linkage to
HPV infection are consistent with this evolutionary pathway [3].
A single patient (patient 5 in Table 1) belonged histologically to
the basaloid type of VSCC, believed to derive through the classic
VIN pathway. Actually, this was the only patient with an established
record of VIN (Table 1). However, the pattern of differential expres-
sion of the 1077 genes that were analyzed was not different from the
rest of the samples derived through the differentiated VIN pathway
(Figure 2). These data imply that, at the status of VSCC, the mo-
lecular phenotypes of the end points of the two pathways exhibit
similar sets of differentially expressed genes. Comparison of the
whole data sets of the VIN study [16] with our study revealed only
158 common genes present in both sets. Of these, 21 genes exhib-
ited common up-regulation and 121 common down-regulation,
thus establishing for the first time the discrete pattern of gene
expression between the two entities. Furthermore, several genes
involved in detoxification, tumor suppression, and RNA cleavage,
among others, displayed a significant gradual down-regulation
during the transition from VIN to VSCC, a pattern consistent
with the anticipated operating mechanisms of sequential carcino-
genesis [29].
Our study revealed also for the first time the presence of a subset
of VSCC patients, regardless of the clinical stage or pathologic diag-
nosis, exhibiting a unique set of 125 upregulated genes involved in
cell death, cell-to-cell signaling and interaction, cellular development,
cellular growth and proliferation, cellular movement, and cellular as-
sembly and organization (Figure 2 and Table W2). These data pro-
vide the impetus for further studies on the functional role of this set
of genes on the natural history of the disease and on the elucidation
of the mechanisms for the generation of these molecular phenotypes.
In conclusion, in the present study, we have documented that
vulvar neoplasia, and specifically VSCC, is consistent with a status
of abnormal cell signaling, proliferation, and remodeling of ECM,
being quite distinct from the described features of its premalignant
state of VIN.
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Figure W1. PCA of the 1077 significant genes. This set of genes
displayed either a greater than 2-fold or a less than −2-fold change
of differential expression (P< .01). The first two components (1 and
2) can capture 92.8% of the variability of the samples. The separa-
tion between tumor samples (T1, T2, T3, T4, T5) and normal samples
(N1, N2, N3, N4, N5) can be seen from the first component.
Table W2. Distinct Set of 125 Genes Differentially Upregulated among the VSCC Patients.
Affymetrix ID Symbol Entrez Gene Name Type(s) Fold Change P
204322_at GOLIM4 Golgi integral membrane protein 4 Other 6.50 .00
207036_x_at GRIN2D Glutamate receptor, ionotropic,
N -methyl D-aspartate 2D
Ion channel 5.90 .00
216419_at CROCC Ciliary rootlet coiled coil, rootletin Other 5.54 .00
205285_s_at FYB FYN binding protein Other 5.36 .00
210850_s_at ELK1 ELK1, member of ETS oncogene family Transcription regulator 5.04 .00
211652_s_at LBP Lipopolysaccharide binding protein Transporter 5.00 .00
220204_s_at BMP8A Bone morphogenetic protein 8a Growth factor 4.97 .00
210523_at BMPR1B Bone morphogenetic protein receptor,
type IB
Kinase 4.89 .00
207412_x_at CELP Carboxyl ester lipase pseudogene Other 4.68 .00
214750_at PLAC4 Placenta-specific 4 Other 4.67 .00
217150_s_at NF2 Neurofibromin 2 (merlin) Other 4.66 .00
205914_s_at GRIN1 Glutamate receptor, ionotropic,
N -methyl D-aspartate 1
Ion channel 4.63 .00
204907_s_at BCL3 B-cell CLL/lymphoma 3 Transcription regulator 4.53 .00
217070_at MTHFR Methylenetetrahydrofolate reductase
(NAD[P]H)
Enzyme 4.51 .00
213277_at ZFP36L1 Zinc finger protein 36, C3H type-like 1 Transcription regulator 4.37 .00
207312_at PHKG1 Phosphorylase kinase, γ1 (muscle) Kinase 4.35 .00
207915_at LOC100293553 Similar to L-myc-2 protein Other 4.35 .00
220209_at PYY2 Peptide YY, 2 (seminal plasmin) Other 4.27 .00
206602_s_at HOXD3 Homeobox D3 Transcription regulator 4.25 .00
215538_at LARGE Like-glycosyltransferase Enzyme 4.19 .00
207462_at GLRA2 Glycine receptor, α2 Ion channel 4.18 .00
221285_at ST8SIA2 ST8 α-N -acetyl-neuraminide
α-2,8-sialyltransferase 2
Enzyme 4.09 .00
215771_x_at RET Ret proto-oncogene Kinase 4.05 .00
216838_at LOC92249 Hypothetical LOC92249 Other 4.04 .00
220423_at PLA2G2D Phospholipase A2, group IID Enzyme 4.03 .00
220657_at KLHL11 Kelch-like 11 (Drosophila) Other 3.91 .00
214485_at ODF1 Outer dense fiber of sperm tails 1 Other 3.89 .00
221313_at GPR52 G protein–coupled receptor 52 G protein–coupled receptor 3.87 .00
208571_at ANP32A Acidic (leucine-rich) nuclear phosphoprotein
32 family, member A
Other 3.84 .00
207366_at KCNS1 Potassium voltage-gated channel, delayed-rectifier,
subfamily S, member 1
Ion channel 3.82 .00
207138_at PHF2 PHD finger protein 2 Other 3.81 .00
208157_at SIM2 Single-minded homolog 2 (Drosophila) Transcription regulator 3.81 .00
204179_at MB Myoglobin Transporter 3.77 .00
204535_s_at REST RE1-silencing transcription factor Transcription regulator 3.76 .00
215292_s_at MKL1 Megakaryoblastic leukemia (translocation) 1 Transcription regulator 3.69 .00
206892_at AMHR2 Anti–mullerian hormone receptor, type II Kinase 3.68 .00
220445_s_at CSAG2 CSAG family, member 2 Other 3.66 .00
205177_at TNNI1 Troponin I type 1 (skeletal, slow) Other 3.63 .00
206798_x_at DLEC1 (includes EG:9940) Deleted in lung and esophageal cancer 1 Other 3.61 .00
206768_at RPL3L Ribosomal protein L3-like Other 3.59 .00
210326_at AGXT Alanine-glyoxylate aminotransferase Enzyme 3.59 .00
211484_s_at DSCAM Down syndrome cell adhesion molecule Other 3.58 .00
210301_at XDH Xanthine dehydrogenase Enzyme 3.58 .01
208323_s_at ANXA13 Annexin A13 Other 3.56 .00
211253_x_at PYY Peptide YY Other 3.55 .00
208495_at TLX3 T-cell leukemia homeobox 3 Transcription regulator 3.50 .00
211900_x_at CD6 CD6 molecule Transmembrane receptor 3.50 .00
220068_at VPREB3 Pre–B lymphocyte 3 Other 3.46 .00
396_f_at EPOR Erythropoietin receptor Transmembrane receptor 3.45 .00
210483_at LOC254896 Hypothetical LOC254896 Other 3.45 .00
216881_x_at PRB4 Proline-rich protein BstNI subfamily 4 Other 3.43 .00
220808_at THEG Theg homolog (mouse) Other 3.42 .00
206210_s_at CETP Cholesteryl ester transfer protein, plasma Enzyme 3.41 .00
211174_s_at CCKAR Cholecystokinin A receptor G protein–coupled receptor 3.40 .00
220542_s_at PLUNC Palate, lung and nasal epithelium associated Other 3.37 .00
214206_at PPIL6 Peptidylprolyl isomerase (cyclophilin)-like 6 Enzyme 3.36 .00
207537_at PFKFB1 6-Phosphofructo-2-kinase/fructose-2,
6-biphosphatase 1
Kinase 3.34 .00
206746_at BFSP1 Beaded filament structural protein 1, filensin Enzyme 3.34 .00
208409_at SLC14A2 Solute carrier family 14 (urea transporter),
member 2
Transporter 3.34 .00
215687_x_at PLCB1 Phospholipase C, β 1 (phosphoinositide-specific) Enzyme 3.34 .00
218600_at LIMD2 LIM domain containing 2 Other 3.30 .00
213640_s_at LOX Lysyl oxidase Enzyme 3.29 .00
220561_at IGF2AS Insulin-like growth factor 2 antisense Other 3.28 .00
Table W2. (continued )
Affymetrix ID Symbol Entrez Gene Name Type(s) Fold Change P
211483_x_at CAMK2B Calcium/calmodulin–dependent
protein kinase II β
Kinase 3.21 .00
211266_s_at GPR4 G protein–coupled receptor 4 G protein–coupled receptor 3.17 .00
205502_at CYP17A1 Cytochrome P450, family 17,
subfamily A, polypeptide 1
Enzyme 3.15 .00
222124_at HIF3A Hypoxia-inducible factor 3, α subunit Transcription regulator 3.14 .00
208466_at RAB3D RAB3D, member RAS oncogene family Enzyme 3.13 .00
221336_at ATOH1 Atonal homolog 1 (Drosophila) Transcription regulator 3.10 .00
216546_s_at CHI3L1 Chitinase 3-like 1
(cartilage glycoprotein-39)
Enzyme 3.10 .00
205708_s_at TRPM2 Transient receptor potential
cation channel, subfamily M,
member 2
Ion channel 3.09 .00
221602_s_at FAIM3 Fas apoptotic inhibitory molecule 3 Other 3.09 .00
206933_s_at H6PD Hexose-6-phosphate dehydrogenase
(glucose 1-dehydrogenase)
Enzyme 3.08 .00
39318_at TCL1A T-cell leukemia/lymphoma 1A Other 3.08 .00
208130_s_at TBXAS1 Thromboxane A synthase 1 (platelet) Enzyme 3.06 .00
205487_s_at VGLL1 Vestigial-like 1 (Drosophila) Transcription regulator 3.06 .00
214228_x_at TNFRSF4 Tumor necrosis factor receptor
superfamily, member 4
Transmembrane receptor 3.04 .00
207509_s_at LAIR2 Leukocyte-associated immunoglobulin-like
receptor 2
Other 3.03 .00
206231_at KCNN1 Potassium intermediate/small conductance
calcium-activated channel, subfamily N,
member 1
Ion channel 3.03 .00
216993_s_at COL11A2 Collagen, type XI, α2 Other 3.01 .00
203444_s_at MTA2 Metastasis associated 1 family, member 2 Transcription regulator 3.00 .00
215328_at EFR3B EFR3 homolog B (S. cerevisiae) Other 2.99 .00
221350_at HOXC8 (includes EG:3224) Homeobox C8 Transcription regulator 2.98 .00
210637_at TACR1 Tachykinin receptor 1 G protein–coupled receptor 2.97 .00
205468_s_at IRF5 Interferon regulatory factor 5 Transcription regulator 2.95 .00
211336_x_at LILRB1 Leukocyte immunoglobulin-like receptor,
subfamily B (with TM and
ITIM domains), member 1
Other 2.94 .00
215685_s_at DLX2 Distal-less homeobox 2 Transcription regulator 2.90 .00
220485_s_at SIRPG Signal-regulatory protein γ Other 2.88 .00
208513_at FOXB1 Forkhead box B1 Transcription regulator 2.86 .00
208377_s_at CACNA1F Calcium channel, voltage-dependent,
L type, α 1F subunit
Ion channel 2.84 .00
220344_at C11ORF16 Chromosome 11 open reading frame 16 Other 2.83 .00
203483_at SEMA4G Sema domain, immunoglobulin domain (Ig),
transmembrane domain (TM) and short
cytoplasmic domain, (semaphorin) 4G
Other 2.78 .00
205733_at BLM Bloom syndrome, RecQ helicase-like Enzyme 2.78 .00
221578_at RASSF4 Ras association (RalGDS/AF-6) domain
family member 4
Other 2.77 .00
220106_at NPC1L1 NPC1 (Niemann-Pick disease, type C1,
gene)-like 1
Transporter 2.75 .00
205820_s_at APOC3 Apolipoprotein C-III Transporter 2.75 .00
217258_x_at LOC100290557 Similar to hCG91935 Other 2.74 .00
204325_s_at NF1 Neurofibromin 1 Other 2.73 .00
214357_at C1ORF105 Chromosome 1 open reading frame 105 Other 2.69 .00
205537_s_at VAV2 Vav 2 guanine nucleotide exchange factor Other 2.66 .00
203838_s_at TNK2 Tyrosine kinase, nonreceptor, 2 Kinase 2.66 .00
207111_at EMR1 Egf-like module containing, mucin-like,
hormone receptor-like 1
G protein–coupled receptor 2.66 .00
214609_at PHOX2A Paired-like homeobox 2a Transcription regulator 2.66 .00
206859_s_at PAEP Progestagen-associated endometrial protein Other 2.66 .01
206237_s_at NRG1 Neuregulin 1 Growth factor 2.65 .00
201107_s_at THBS1 Thrombospondin 1 Other 2.63 .00
210184_at ITGAX Integrin, α X (complement component 3
receptor 4 subunit)
Other 2.63 .00
204948_s_at FST Follistatin Other 2.56 .00
213724_s_at PDK2 Pyruvate dehydrogenase kinase, isozyme 2 Kinase 2.56 .00
215833_s_at SPPL2B Signal peptide peptidase-like 2B Peptidase 2.55 .00
205834_s_at PART1 Prostate androgen–regulated transcript 1
(non–protein coding)
Other 2.54 .00
202895_s_at SIRPA Signal regulatory protein α Phosphatase 2.54 .00
211312_s_at WISP1 WNT1-inducible signaling pathway
protein 1
Other 2.53 .00
212525_s_at H2AFX H2A histone family, member X Other 2.51 .00
204561_x_at APOC2 Apolipoprotein C-II Transporter 2.51 .01
Table W2. (continued )
Affymetrix ID Symbol Entrez Gene Name Type(s) Fold Change P
206273_at SLMO1 Slowmo homolog 1 (Drosophila) Other 2.51 .00
216963_s_at GAP43 Growth-associated protein 43 Other 2.47 .00
211835_at IGKV1-5 Immunoglobulin κ variable 1-5 Other 2.46 .00
209999_x_at SOCS1 Suppressor of cytokine signaling 1 Other 2.45 .00
206110_at HIST1H3H Histone cluster 1, H3h Other 2.38 .00
206917_at GNA13 Guanine nucleotide binding protein
(G protein), α13
Enzyme 2.38 .00
211426_x_at GNAQ Guanine nucleotide binding protein
(G protein), q polypeptide
Enzyme 2.37 .00
214969_at MAP3K9 Mitogen-activated protein kinase
kinase kinase 9
Kinase 2.32 .01
222075_s_at OAZ3 (includes EG:51686) Ornithine decarboxylase antizyme 3 Other 2.08 .00
205017_s_at MBNL2 Muscle blind-like 2 (Drosophila) Other 2.02 .00
Figure W2. The top 20 significant pathways identified to be affected in VSCC. The pathways are depicted in descending order according
to their significance (−log[P]).
Table W3. Pattern of Expression of Selected Genes in Our Series Proposed to Be Involved in Vulvar Carcinoma [15].
Affymetrix ID Gene Symbol Description Fold Change P Involvement
211963_s_at ARPC5 Actin-related protein 2/3 complex, subunit 5, 16 kd 1.38 <.05 P, CO
208712_at CCND1 Cyclin D1 −2.6 <.05 P
216836_s_at ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma −1.99 <.05 P, CO
211527_x_at VEGFA Vascular endothelial growth factor A 3.3 <.01 P, CO
205015_s_at TGFA Transforming growth factor, α 1.96 <.01 P
211607_x_at EGFR Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene 1.82 <.01 P
203685_at BCL2 B-cell CLL/lymphoma 2 −2.58 <.01 CO
222038_s_at NME1 Nonmetastatic cells 1, protein (NM23A) expressed in 1.28 <.01 CO
Genes that displayed P < .05 were considered significant.
CO indicates clinical outcome; P, pathogenesis and/or progression.
Table W4. The 21 Genes Upregulated Both in VIN [16] and in VSCC.
Gene Symbol Fold Change
VIN VSCC
ATAD2 8.3 2.07792
TPX2 6.2 3.61455
KIF4A 6 2.36118
MKI67 5.7 3.19299
UBE2C 5.1 2.97112
CENPE 4.7 2.40559
CDCA3 3.9 2.01355
BIRC5 3.4 2.39378
SSX2IP 3.3 2.51571
FEN1 3.2 2.14005
PRDM1 2.9 2.24525
WHSC1 2.3 2.534
H2AFX 2.3 2.07774
BLM 2.2 2.62143
NRAS 2.1 2.3029
RAD21 2 3.3336
SKP2 2 2.00554
DDX3X 1.5 3.29372
MKL1 1.3 2.4423
NCOA3 1.3 2.2841
CWF19L1 1.3 2.02551
Table W5. The 121 Genes Downregulated Both in VIN [16] and in VSCC.
Gene Symbol Fold Change
VIN VSCC
ZNF264 −1.4 −3.8994
IL11RA −1.5 −3.05982
ZKSCAN1 −1.5 −2.9987
PARD3 −1.5 −2.81519
DALRD3 −1.5 −2.64142
NCOA1 −1.5 −2.50503
HEBP1 −1.5 −2.44703
ANXA11 −1.5 −2.08434
RPL15 −1.5 −2.03454
ALDH3A2 −1.6 −3.18065
LANCL1 −1.6 −2.24502
PGLS −1.6 −2.04624
CPEB1 −1.6 −2.02167
NDRG2 −1.7 −3.12949
SPTBN1 −1.7 −3.03342
KIAA0495 −1.7 −2.58371
TCF4 −1.7 −2.35249
ADD1 −1.7 −2.13498
MRC2 −1.7 −2.03175
TCF7L2 −1.8 −2.92909
DIAPH2 −1.8 −2.82797
CIRBP −1.8 −2.54922
C11orf2 −1.8 −2.3754
MSRB2 −1.8 −2.34272
TACC1 −1.8 −2.29988
SNRPN −1.8 −2.22426
MYLIP −1.8 −2.20568
SMARCD3 −1.8 −2.16835
CDH5 −1.8 −2.13741
NFASC −1.8 −2.13496
GPD1L −1.9 −5.15806
GLTSCR2 −1.9 −3.34728
GABARAPL1 −1.9 −3.24118
SESN1 −1.9 −3.11739
LRIG1 −1.9 −2.78016
VWF −1.9 −2.5838
INPP5A −1.9 −2.07477
MGLL −2 −5.28424
NFIB −2 −4.05748
KIT −2 −3.53782
SPRY2 −2 −2.89128
PGRMC2 −2 −2.84929
CRTAP −2 −2.20146
MPDZ −2 −2.02107
C14orf139 −2.1 −3.10306
DDAH2 −2.1 −2.81674
TXNIP −2.1 −2.41892
RASL12 −2.1 −2.25767
PTRF −2.1 −2.24747
EFEMP2 −2.1 −2.04532
SFXN3 −2.1 −1.99738
EDNRB −2.2 −4.34131
CD302 −2.2 −3.59998
ZBTB20 −2.2 −3.45299
ARMCX2 −2.2 −2.94354
PKIG −2.2 −2.33898
SPRED2 −2.2 −2.30238
TRPC1 −2.2 −2.15492
CREB3L2 −2.2 −2.02039
HYMAI −2.3 −4.3541
MAOB −2.3 −3.2713
CYP3A5 −2.3 −3.15272
PGCP −2.3 −3.04717
NR3C2 −2.3 −2.96605
ANG −2.3 −2.43047
AXL −2.3 −2.26289
LMO2 −2.3 −2.1959
FCGRT −2.3 −2.1382
MAGEH1 −2.3 −2.04363
FZD7 −2.4 −7.18064
AQP1 −2.4 −4.51407
DCN −2.4 −4.47396
Table W5. (continued )
Gene Symbol Fold Change
VIN VSCC
GSN −2.4 −2.25669
PLAGL1 −2.5 −9.87516
GULP1 −2.5 −8.52546
RPS6KA2 −2.5 −4.35973
MAOA −2.5 −4.04476
ADD3 −2.5 −3.89709
CAPN3 −2.5 −3.60124
CDKN1C −2.5 −3.27147
DAB2 −2.5 −3.19438
PHYH −2.5 −2.61108
COL6A2 −2.5 −2.46742
CD34 −2.5 −2.19136
GHR −2.6 −3.53847
PIK3R1 −2.6 −2.99663
MITF −2.6 −2.98432
COX7A1 −2.6 −2.88864
FGFR1 −2.6 −2.51164
TBC1D16 −2.6 −2.18834
NR2F2 −2.7 −4.90417
PMP22 −2.7 −2.80892
NDN −2.8 −3.53364
NRN1 −2.9 −3.29245
MAP1B −2.9 −3.28567
PDZRN3 −3 −3.1651
SEMA6A −3 −2.41748
FBXL7 −3 −2.39799
RNASE4 −3.1 −8.29695
FBLN1 −3.1 −7.09602
GPX3 −3.2 −9.32619
TGFBR3 −3.2 −8.56243
RBPMS −3.2 −5.32857
CLU −3.2 −4.61226
GPM6B −3.2 −4.61175
OLFML1 −3.2 −3.09531
DKK3 −3.2 −2.81436
C5orf4 −3.2 −2.65594
ZNF423 −3.3 −4.38287
RAI2 −3.3 −3.6086
SGCE −3.3 −3.33792
MLPH −3.3 −3.30416
PPAP2B −3.5 −4.87442
OLFML3 −3.5 −3.04505
TIMP3 −3.7 −5.33116
SLIT2 −4.1 −5.59815
AR −4.6 −3.58597
LPHN3 −4.6 −2.1185
IGFBP6 −4.8 −4.1508
FHL1 −4.9 −8.24882
EDN3 −12.1 −15.5818
